A High Count of Gene Changes Is Rare in Children's Solid Tumors
Original title: Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This only counted gene changes in old tumor samples. No treatment was tested.
The short version
Very few tumors in children had a high count of gene changes.
What was studied. Researchers looked back at tumor samples from 3533 children under 18. The samples were tested for gene changes between 2013 and 2023.
What they found. A high count of gene changes was found in 1.42% of these tumors. It was more common in kids aged 12 to 17 than in kids under 12. The rates were 2.17% and 0.98%. In every tumor group it was under 3%. That included brain tumors and nerve tumors.
What this means, and what it doesn't
What it could mean: A high count of gene changes has been linked to response to a drug called pembrolizumab. This study says that finding is rare in children. Most children with solid tumors will not have it. Gene testing can still show the few who do.
What it doesn't mean: This does not mean there is a new treatment. The team only counted gene changes in stored tumor samples. They did not give any drug or test one in children. It does not show that pembrolizumab helps children. This is early background science, far from day to day care. It is not a promise of a cure.
Source: PubMed, August 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.